Damian Kettlewell

Part of Origin Therapeutics Holdings, Inc., Clairvoyant Therapeutics, Inc. is a Canadian biotechnology company focused on mental health through psilocybin therapy. The company is based in Vancouver, Canada. Clairvoyant is changing the face of psychedelic therapy with a speed-to-market clinical strategy designed to enable psilocybin therapy in the US, the EU, and to treat patients living with alcohol use disorder (AUD) beginning in 2026. Clairvoyant's exceptional team, with a proven clinical track record and deep drug development experience, has made it the most advanced company developing psilocybin therapy for the treatment of AUD. Clairvoyant was founded by Damian Kettlewell, Thomas Digby, and has been led by Damian Kettlewell as CEO since incorporation. Clairvoyant Therapeutics was acquired by Origin Therapeutics Holdings, Inc. on July 07, 2022.

Part of Origin Therapeutics Holdings, Inc., Clairvoyant Therapeutics, Inc. is a Canadian biotechnology company focused on mental health through psilocybin therapy. The company is based in Vancouver, Canada. Clairvoyant is changing the face of psychedelic therapy with a speed-to-market clinical strategy designed to enable psilocybin therapy in the US, the EU, and to treat patients living with alcohol use disorder (AUD) beginning in 2026. Clairvoyant's exceptional team, with a proven clinical track record and deep drug development experience, has made it the most advanced company developing psilocybin therapy for the treatment of AUD. Clairvoyant was founded by Damian Kettlewell, Thomas Digby, and has been led by Damian Kettlewell as CEO since incorporation. Clairvoyant Therapeutics was acquired by Origin Therapeutics Holdings, Inc. on July 07, 2022.

Part of Origin Therapeutics Holdings, Inc., Clairvoyant Therapeutics, Inc. is a Canadian biotechnology company focused on mental health through psilocybin therapy. The company is based in Vancouver, Canada. Clairvoyant is changing the face of psychedelic therapy with a speed-to-market clinical strategy designed to enable psilocybin therapy in the US, the EU, and to treat patients living with alcohol use disorder (AUD) beginning in 2026. Clairvoyant's exceptional team, with a proven clinical track record and deep drug development experience, has made it the most advanced company developing psilocybin therapy for the treatment of AUD. Clairvoyant was founded by Damian Kettlewell, Thomas Digby, and has been led by Damian Kettlewell as CEO since incorporation. Clairvoyant Therapeutics was acquired by Origin Therapeutics Holdings, Inc. on July 07, 2022.

Part of Origin Therapeutics Holdings, Inc., Clairvoyant Therapeutics, Inc. is a Canadian biotechnology company focused on mental health through psilocybin therapy. The company is based in Vancouver, Canada. Clairvoyant is changing the face of psychedelic therapy with a speed-to-market clinical strategy designed to enable psilocybin therapy in the US, the EU, and to treat patients living with alcohol use disorder (AUD) beginning in 2026. Clairvoyant's exceptional team, with a proven clinical track record and deep drug development experience, has made it the most advanced company developing psilocybin therapy for the treatment of AUD. Clairvoyant was founded by Damian Kettlewell, Thomas Digby, and has been led by Damian Kettlewell as CEO since incorporation. Clairvoyant Therapeutics was acquired by Origin Therapeutics Holdings, Inc. on July 07, 2022.